Compare · BCLI vs MRNA
BCLI vs MRNA
Side-by-side comparison of Brainstorm Cell Therapeutics Inc. (BCLI) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCLI and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 220.2x BCLI ($111.4M).
- MRNA has hit the wire 11 times in the past 4 weeks while BCLI has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 0 for BCLI).
- Company
- Brainstorm Cell Therapeutics Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $111.4M
- $24.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BCLI
- SEC Form 3 filed by new insider Pitts Peter Joe
- SEC Form EFFECT filed by Brainstorm Cell Therapeutics Inc.
- BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
- President & CEO Lebovits Chaim was granted 1,800,000 shares, increasing direct ownership by 896% to 2,000,960 units (SEC Form 4)
- EVP & Chief Business Officer Yablonka Uri was granted 150,000 shares, increasing direct ownership by 219% to 218,464 units (SEC Form 4)
- Officer Patlis Alla was granted 100,000 shares, increasing direct ownership by 225% to 144,349 units (SEC Form 4)
- Director Frenkel Jacob A was granted 200,000 shares, increasing direct ownership by 457% to 243,777 units (SEC Form 4)
- Director Arbel Irit was granted 120,000 shares, increasing direct ownership by 292% to 161,054 units (SEC Form 4)
- Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester